DelveInsight’s “Metastatic Triple Negative Breast Cancer (mTNBC)” report delivers an in-depth understanding of the Metastatic Triple Negative Breast Cancer (mTNBC), historical and forecasted epidemiology as well as the Metastatic Triple Negative Breast Cancer market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Key Highlights from the Metastatic Triple Negative Breast Cancer Market Report:
Request for Sample Pages: https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-market
Metastatic Triple Negative Breast Cancer (mTNBC) market report provides current treatment practices, emerging drugs, Metastatic Triple Negative Breast Cancer (mTNBC) market share of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy market Size from 2018 to 2030 segmented by seven major markets.
The Report also lays forward current mTNBC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Metastatic Triple Negative Breast Cancer: Disease Overview
Metastatic Triple Negative Breast Cancer is characterized as a metastatic tumor in which the estrogen and progesterone (ER/PR) receptors are negative by immunohistochemistry (IHC) and there is no overexpression of HER2 by immunohistochemistry (IHC) or no gene amplification by fluorescence in situ hybridization technique. TNBC (ER-PR-HER2-) and other breast cancers have different epidemiological risk factor profiles.
According to breastcancer.org, about 70% of breast cancers diagnosed in people who have an inherited BRCA mutation, particularly BRCA1, are triple-negative.
TNBCs are slightly larger and of higher grade than non-TNBCs, according to secondary sources, but they are less likely to have lymph node metastases.
Metastatic Triple Negative Breast Cancer Market
Metastatic Triple Negative Breast Cancer Treatment Landscape
Currently, the treatment paradigm for mTNBC includes few treatment options such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery and radiation.
Few US FDA approved drugs, such as:
Various off label drugs are used for treating mTNBC which include:
Metastatic Triple Negative Breast Cancer Market is expected to witness the launch of upcoming therapies by key pharmaceutical companies including Hoffman-La Roche, Infinity Pharmaceuticals, Cytodyn, and several others. The launch of Ipatasertib (Hoffman-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (Cytodyn), etc. is anticipated to provide a major push to the growth of the mTNBC market size in the forecast period 2018-30 in the 7MM.
Learn more about market insights @ https://www.delveinsight.com/sample-request/metastatic-triple-negative-breast-cancer-market
Metastatic Triple Negative Breast Cancer Emerging Drugs
Metastatic Triple Negative Breast Cancer Market Drivers
Metastatic Triple Negative Breast Cancer Market Barriers
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)
Study Period: 2018-30
Key Companies in mTNBC Market: Hoffmann-La Roche, Infinity Pharmaceuticals, HiberCell, CytoDyn, Treadwell Therapeutics, and several others.
Key mTNBC Pipeline therapies: Ipatasertib (RG7440), IPI-549 (Eganelisib), Pembrolizumab (Imprime PGG), Leronlimab (PRO 140), CFI-400945 and several others.
mTNBC Market Segmentation: By Geography, By mTNBC therapies
Analysis: Comparative and conjoint analysis of mTNBC emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Triple Negative Breast Cancer Market Overview at a Glance
3.
Disease Background and Overview: Triple Negative Breast Cancer
4.
Unmet Needs
5.
Epidemiology and Patient Population
6.
Country Wise-Epidemiology of TNBC
7.
Treatment Practices
8.
Marketed Drug Analysis
9.
Emerging Therapies
10.
Metastatic Triple Negative Breast Cancer (mTNBC): 7MM Market Analysis
11.
Market Outlook by Country
12.
Market Drivers
13.
Market Barriers
14.
Appendix
15.
DelveInsight Capabilities
16.
Disclaimer
17.
About DelveInsight
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/metastatic-triple-negative-breast-cancer-market